Hikma Pharmaceuticals (OTCMKTS:HKMPF) Upgraded at Zacks Investment Research


Share on StockTwits

Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The brokerage currently has a $41.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 13.26% from the company’s previous close.

According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “

Other equities analysts also recently issued research reports about the stock. Morgan Stanley downgraded shares of Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 22nd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Tuesday, November 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $41.00.

Shares of Hikma Pharmaceuticals stock remained flat at $$36.20 during trading on Wednesday. 2 shares of the company traded hands, compared to its average volume of 2,400. Hikma Pharmaceuticals has a 52 week low of $19.75 and a 52 week high of $42.00. The firm has a market capitalization of $8.77 billion, a P/E ratio of 24.13 and a beta of 0.42. The business’s 50 day moving average price is $34.83 and its two-hundred day moving average price is $32.44. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.76 and a quick ratio of 1.12.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals.

Read More: Asset Allocation

Get a free copy of the Zacks research report on Hikma Pharmaceuticals (HKMPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.